Efficacy	efficacy	O	O
and	and	O	O
safety	safety	O	O
of	of	O	O
asenapine	asenapine	S_chemical	O
in	in	O	O
a	a	O	O
placebo-	placebo-	O	O
and	and	O	O
haloperidol-controlled	haloperidol-controlled	O	O
trial	trial	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
acute	acute	O	O
exacerbation	exacerbation	O	O
of	of	O	O
schizophrenia	schizophrenia	O	S_disease
.	.	O	O

Asenapine	asenapine	S_chemical	O
is	is	O	O
approved	approved	O	O
by	by	O	O
the	the	O	O
Food	food	O	O
and	and	O	O
Drugs	drugs	O	O
Administration	administration	O	O
in	in	O	O
adults	adults	O	O
for	for	O	O
acute	acute	O	O
treatment	treatment	O	O
of	of	O	O
schizophrenia	schizophrenia	O	S_disease
or	or	O	O
of	of	O	O
manic	manic	O	S_disease
or	or	O	O
mixed	mixed	O	O
episodes	episodes	O	O
associated	associated	O	O
with	with	O	O
bipolar	bipolar	O	S_disease
I	i	O	O
disorder	disorder	O	O
with	with	O	O
or	or	O	O
without	without	O	O
psychotic	psychotic	O	O
features	features	O	O
.	.	O	O

In	in	O	O
a	a	O	O
double-blind	double-blind	O	O
6-week	6-week	O	O
trial	trial	O	O
,	,	O	O
458	458	O	O
patients	patients	O	O
with	with	O	O
acute	acute	O	O
schizophrenia	schizophrenia	O	S_disease
were	were	O	O
randomly	randomly	O	O
assigned	assigned	O	O
to	to	O	O
fixed-dose	fixed-dose	O	O
treatment	treatment	O	O
with	with	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
mg	mg	O	O
twice	twice	O	O
daily	daily	O	O
(	(	O	O
BID	bid	O	O
)	)	O	O
,	,	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
10	10	O	O
mg	mg	O	O
BID	bid	O	O
,	,	O	O
placebo	placebo	O	O
,	,	O	O
or	or	O	O
haloperidol	haloperidol	S_chemical	O
at	at	O	O
4	4	O	O
mg	mg	O	O
BID	bid	O	O
(	(	O	O
to	to	O	O
verify	verify	O	O
assay	assay	O	O
sensitivity	sensitivity	O	O
)	)	O	O
.	.	O	O

With	with	O	O
last	last	O	O
observations	observations	O	O
carried	carried	O	O
forward	forward	O	O
(	(	O	O
LOCF	locf	O	O
)	)	O	O
,	,	O	O
mean	mean	O	O
Positive	positive	O	O
and	and	O	O
Negative	negative	O	O
Syndrome	syndrome	O	O
Scale	scale	O	O
total	total	O	O
score	score	O	O
reductions	reductions	O	O
from	from	O	O
baseline	baseline	O	O
to	to	O	O
endpoint	endpoint	O	O
were	were	O	O
significantly	significantly	O	O
greater	greater	O	O
with	with	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
mg	mg	O	O
BID	bid	O	O
(	(	O	O
-16.2	-16.2	O	O
)	)	O	O
and	and	O	O
haloperidol	haloperidol	S_chemical	O
(	(	O	O
-15.4	-15.4	O	O
)	)	O	O
than	than	O	O
placebo	placebo	O	O
(	(	O	O
-10.7	-10.7	O	O
;	;	O	O
both	both	O	O
P	p	O	O
<	<	O	O
0.05	0.05	O	O
)	)	O	O
;	;	O	O
using	using	O	O
mixed	mixed	O	O
model	model	O	O
for	for	O	O
repeated	repeated	O	O
measures	measures	O	O
(	(	O	O
MMRM	mmrm	O	O
)	)	O	O
,	,	O	O
changes	changes	O	O
at	at	O	O
day	day	O	O
42	42	O	O
were	were	O	O
significantly	significantly	O	O
greater	greater	O	O
with	with	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
and	and	O	O
10	10	O	O
mg	mg	O	O
BID	bid	O	O
(	(	O	O
-21.3	-21.3	O	O
and	and	O	O
-19.4	-19.4	O	O
,	,	O	O
respectively	respectively	O	O
)	)	O	O
and	and	O	O
haloperidol	haloperidol	S_chemical	O
(	(	O	O
-20.0	-20.0	O	O
)	)	O	O
than	than	O	O
placebo	placebo	O	O
(	(	O	O
-14.6	-14.6	O	O
;	;	O	O
all	all	O	O
P	p	O	O
<	<	O	O
0.05	0.05	O	O
)	)	O	O
.	.	O	O

On	on	O	O
the	the	O	O
Positive	positive	O	O
and	and	O	O
Negative	negative	O	O
Syndrome	syndrome	O	O
Scale	scale	O	O
positive	positive	O	O
subscale	subscale	O	O
,	,	O	O
all	all	O	O
treatments	treatments	O	O
were	were	O	O
superior	superior	O	O
to	to	O	O
placebo	placebo	O	O
with	with	O	O
LOCF	locf	O	O
and	and	O	O
MMRM	mmrm	O	O
;	;	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
mg	mg	O	O
BID	bid	O	O
was	was	O	O
superior	superior	O	O
to	to	O	O
placebo	placebo	O	O
on	on	O	O
the	the	O	O
negative	negative	O	O
subscale	subscale	O	O
with	with	O	O
MMRM	mmrm	O	O
and	and	O	O
on	on	O	O
the	the	O	O
general	general	O	O
psychopathology	psychopathology	O	O
subscale	subscale	O	O
with	with	O	O
LOCF	locf	O	O
and	and	O	O
MMRM	mmrm	O	O
.	.	O	O

Treatment-related	treatment-related	O	O
adverse	adverse	O	O
events	events	O	O
(	(	O	O
AEs	aes	O	O
)	)	O	O
occurred	occurred	O	O
in	in	O	O
44	44	O	O
%	%	O	O
and	and	O	O
52	52	O	O
%	%	O	O
,	,	O	O
57	57	O	O
%	%	O	O
,	,	O	O
and	and	O	O
41	41	O	O
%	%	O	O
of	of	O	O
the	the	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
and	and	O	O
10	10	O	O
mg	mg	O	O
BID	bid	O	O
,	,	O	O
haloperidol	haloperidol	S_chemical	O
,	,	O	O
and	and	O	O
placebo	placebo	O	O
groups	groups	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

Extrapyramidal	extrapyramidal	O	B_disease
symptoms	symptoms	O	I_disease
reported	reported	O	O
as	as	O	O
AEs	aes	O	O
occurred	occurred	O	O
in	in	O	O
15	15	O	O
%	%	O	O
and	and	O	O
18	18	O	O
%	%	O	O
,	,	O	O
34	34	O	O
%	%	O	O
,	,	O	O
and	and	O	O
10	10	O	O
%	%	O	O
of	of	O	O
the	the	O	O
asenapine	asenapine	S_chemical	O
at	at	O	O
5	5	O	O
and	and	O	O
10	10	O	O
mg	mg	O	O
BID	bid	O	O
,	,	O	O
haloperidol	haloperidol	S_chemical	O
,	,	O	O
and	and	O	O
placebo	placebo	O	O
groups	groups	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

Across	across	O	O
all	all	O	O
groups	groups	O	O
,	,	O	O
no	no	O	O
more	more	O	O
than	than	O	O
5	5	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
had	had	O	O
clinically	clinically	O	O
significant	significant	O	O
weight	weight	O	O
change	change	O	O
.	.	O	O

Post	post	O	O
hoc	hoc	O	O
analyses	analyses	O	O
indicated	indicated	O	O
that	that	O	O
efficacy	efficacy	O	O
was	was	O	O
similar	similar	O	O
with	with	O	O
asenapine	asenapine	S_chemical	O
and	and	O	O
haloperidol	haloperidol	S_chemical	O
;	;	O	O
greater	greater	O	O
contrasts	contrasts	O	O
were	were	O	O
seen	seen	O	O
in	in	O	O
AEs	aes	O	O
,	,	O	O
especially	especially	O	O
extrapyramidal	extrapyramidal	O	B_disease
symptoms	symptoms	O	I_disease
.	.	O	O

